GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-03-07|

Revolutionizing Eye Disease Treatment with iPSC Therapy

by Kathy Huang
Share To

The Cell & Gene Therapy Research & Development Congress Asia 2023 kicked off in Taipei, Taiwan today, experts in the field of cell and gene therapy gathered here to discuss the emerging advances in the field of cell and gene therapy, the regenerative potential of stem cells, the application of T-cells and CAR-T in the field of immuno-oncology, and more.

iPSC Therapeutics for Eyes Diseases

Xianmin Zeng, Professor at the University of Singapore and President & CEO of RxCell Inc. gave the talk about iPSC therapy treating retinal degenerative diseases. 

cell and gene therapy research and development congress asia 2023
Professor Xianmin Zeng, University of Singapore and President & CEO of RxCell Inc.

Two retinal diseases that lead to blindness are caused by loss of cells: age-related macular degeneration (AMD) and Retinitis pigmentosa (RP). For eye disorders, they are ideal indications for cell therapy regarding eyes’ accessibility, small and confined organ characteristics. 

To develop universal iPSC therapy, RxCell has combined Knock-out and Knock-in gene techniques to generate hypoimmunogenic iPSC cell lines. Mouse model and non-human primate studies show C-Rx-001 presents an effective way to avoid immune rejection. Using autologous cell transplantation and HLA haplobank approach, the single source cell platform possesses the ability to evade immune detection and cure retinal degenerative diseases.

Related Article: Cell & Gene Therapy Congress Asia Day One: Advances in the Research

Advancing Manufacturing Process of iPSC-derived Products

With clinical applications progressing, Zeng shared that RxCell has established a current Good Manufacture Practice (cGMP) iPSC master cell bank for clinical use. Besides, a GMP-compliant manufacturing process for RPC manufacture has been established. 

The cGMP-grade human iPSC-derived retinal photoreceptor precursor cells show no adverse effects in naïve NHP models. In addition, photoreceptor precursors injected into retinal degeneration NHP models demonstrated an ability both to survive and to mature into cone photoreceptors at 3 months post-transplant. 

Enabling Next-Generation Cell Therapies with Deep Tech

Peter Peumans, CTO of IMEC shared the application of deep tech to the healthcare field. As a world-leading R&D and innovation hub in nanoelectronics and digital technologies, IMEC connects digital technology to life science technology, including cell assays, computational microscopy, smart neuroprobes, and next-gen omics.

Peter Peumans, CTO of IMEC

Peumans noted this new toolset will allow for high-throughput cell selection and editing based on cell surface repertoire or functional assays with single cell precision. For example, IMEC has developed a compact, disposable cell sorter. It enables the sorting of blood cells in minutes, reporting the result to point-of-care and early cancer diagnostics applications. 

Good Data Integrity in Cell & Gene Therapy Products

Following up, Anthony Colenburg Sr, Director & Site Head of Quality from Sutro Biopharma addressed the quality & regulatory expectations of cell & gene therapy products.

In Colenburg’s talk, he pointed out the importance of data integrity, since it affects product consistency, safety as well as efficacy. 

Anthony Colenburg, Sr. Director & Site Head of Quality of Sutro Biopharma

Colenburg also gave a brief introduction on good data integrity and documentation practice standard. Good Data Integrity and Documentation Practices describe standards by which records are created and maintained. It is required by the U.S. FDA, EMA, as well as other worldwide regulatory guidelines. Not only does it ensure the product safety, identity, strength, quality, and Purity/Potency (SISQP), it also provides evidence to the regulatory agencies that procedures were followed, and the products are being manufactured as claimed. Colenburg emphasized that it’s important to establish confidence in the quality of manufacturing, testing and final products at every stage/phase.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando
2024-11-26
FDA Approves Kebilidi: First Brain-Delivered Gene Therapy for Rare AADC Disease
2024-11-15
AusBiotech 2024 to Highlight Global Areas of Interest, Current Trends, and Research Directives in Australia’s Diverse Biotech Industry
2024-10-25
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top